Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.

@article{Kopp2009CombinationOO,
  title={Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.},
  author={Matthias V Kopp and Eckard H. Hamelmann and Stefan Zielen and Wolfgang Kamin and K. Bergmann and Christian Sieder and Stefan Stenglein and Stefan Seyfried and Ulrich Wahn},
  journal={Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology},
  year={2009},
  volume={39 2},
  pages={
          271-9
        }
}
BACKGROUND The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side-effects. OBJECTIVE The aim of this study was to study the effect of omalizumab, a monoclonal anti-IgE antibody, in combination with SIT in patients with seasonal allergic rhinoconjunctivitis (SAR) and co-morbid seasonal allergic asthma (SAA) incompletely controlled by conventional pharmacotherapy. METHODS A randomized, double-blind, placebo-controlled, multi-centre trial was performed… CONTINUE READING
Highly Cited
This paper has 35 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 citations